JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

The JAK2(V617F) mutation is frequently observed in classical myeloproliferative disorders, and disease progression is associated with a biallelic acquisition of the mutation occurring by mitotic recombination. In this study, we examined whether JAK2 activation could lead to increased homologous recombination (HR) and genetic instability. In a Ba/F3 cell line expressing the erythropoietin (EPO) receptor, mutant JAK2(V617F) and, to a lesser extent, wild-type (wt) JAK2 induced an increase in HR activity in the presence of EPO without modifying nonhomologous end-joining efficiency. Moreover, a marked augmentation in HR activity was found in CD34(+)-derived cells isolated from patients with polycythemia vera or primitive myelofibrosis compared with control samples. This increase was associated with a spontaneous RAD51 foci formation. As a result, sister chromatid exchange was 50% augmented in JAK2(V617F) Ba/F3 cells compared with JAK2wt cells. Moreover, JAK2 activation increased centrosome and ploidy abnormalities. Finally, in JAK2(V617F) Ba/F3 cells, we found a 100-fold and 10-fold increase in mutagenesis at the HPRT and Na/K ATPase loci, respectively. Together, this work highlights a new molecular mechanism for HR regulation mediated by JAK2 and more efficiently by JAK2(V617F). Our study might provide some keys to understand how a single mutation can give rise to different pathologies.

[1]  A. Tefferi,et al.  Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates , 2008, European journal of haematology.

[2]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[3]  J. Ihle,et al.  Jak2 FERM Domain Interaction with the Erythropoietin Receptor Regulates Jak2 Kinase Activity , 2007, Molecular and Cellular Biology.

[4]  W. Vainchenker,et al.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.

[5]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[6]  P. Campbell,et al.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.

[7]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[8]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[9]  E. Markova,et al.  Relative contribution of homologous recombination and non-homologous end-joining to DNA double-strand break repair after oxidative stress in Saccharomyces cerevisiae. , 2006, DNA repair.

[10]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[11]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[12]  A. Fischer,et al.  Cernunnos, a Novel Nonhomologous End-Joining Factor, Is Mutated in Human Immunodeficiency with Microcephaly , 2006, Cell.

[13]  H. Lodish,et al.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[15]  K. Kaushansky.  On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. , 2005, Hematology. American Society of Hematology. Education Program.

[16]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[17]  F. Daboussi,et al.  Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses , 2005, Oncogene.

[18]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[19]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[20]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[21]  J. Desimone.  The evolving role of DNA demethylating agents in the treatment of sickle cell disease and thalassemia. , 2004, Seminars in hematology.

[22]  C. Desmaze,et al.  Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. , 2004, Molecular cell.

[23]  Xuedong Liu,et al.  High-throughput gateway bicistronic retroviral vectors for stable expression in mammalian cells: exploring the biologic effects of STAT5 overexpression. , 2004, DNA and cell biology.

[24]  Y. Saintigny,et al.  p53's double life: transactivation-independent repression of homologous recombination. , 2004, Trends in genetics : TIG.

[25]  J. Spivak.  The chronic myeloproliferative disorders: clonality and clinical heterogeneity. , 2004, Seminars in hematology.

[26]  J. Aten,et al.  Dynamics of DNA Double-Strand Breaks Revealed by Clustering of Damaged Chromosome Domains , 2004, Science.

[27]  J. Thacker,et al.  Homologous recombination deficiency leads to profound genetic instability in cells derived from Xrcc2-knockout mice. , 2003, Cancer research.

[28]  S. Lambert,et al.  Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells , 2003, Oncogene.

[29]  L. Wiesmüller,et al.  DNA Substrate Dependence of p53-Mediated Regulation of Double-Strand Break Repair , 2002, Molecular and Cellular Biology.

[30]  C. Griffin.  Aneuploidy, centrosome activity and chromosome instability in cells deficient in homologous recombination repair. , 2002, Mutation research.

[31]  K. Haigis,et al.  Intestinal adenomas can develop with a stable karyotype and stable microsatellites , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Lambert,et al.  Inactivation of the RAD51 recombination pathway stimulates UV-induced mutagenesis in mammalian cells , 2002, Oncogene.

[33]  R. Fishel,et al.  Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis , 2002, Molecular and Cellular Biology.

[34]  G. Mufti,et al.  Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. , 2002, Cancer research.

[35]  David J. Chen,et al.  DNA-dependent protein kinase suppresses double-strand break-induced and spontaneous homologous recombination , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Fishel,et al.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. , 2001, Molecular cell.

[37]  R. Mesa,et al.  Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[38]  H. Stürzbecher,et al.  Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer , 2000, International journal of cancer.

[39]  A. Gazdar,et al.  Abnormal expression of BRCA1 and BRCA1‐interactive DNA‐repair proteins in breast carcinomas , 2000, International journal of cancer.

[40]  F. Fabre,et al.  Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases , 2000, Nature Genetics.

[41]  H. Stürzbecher,et al.  DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma , 2000, Oncogene.

[42]  M. Dardalhon,et al.  DNA damage-inducible and RAD52-independent repair of DNA double-strand breaks in Saccharomyces cerevisiae. , 2000, Genetics.

[43]  T. Barbui,et al.  Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG , 2000, Leukemia & lymphoma.

[44]  G. Barosi,et al.  The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia , 1999, British journal of haematology.

[45]  P. Baumann,et al.  DNA end-joining catalyzed by human cell-free extracts. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Jasin,et al.  Homology-directed repair is a major double-strand break repair pathway in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Akira Shinohara,et al.  Rad51‐deficient vertebrate cells accumulate chromosomal breaks prior to cell death , 1998, The EMBO journal.

[48]  D. Casciano,et al.  The mutagenic response at the ouabain resistance locus in T cells of mice exposed to N-ethyl-N-nitrosourea parallels the response at the Hprt locus and correlates with mutation target size. , 1997, Carcinogenesis.

[49]  H. Crissman,et al.  Cell cycle-dependent protein expression of mammalian homologs of yeast DNA double-strand break repair genes Rad51 and Rad52. , 1997, Mutation research.

[50]  P. Patel,et al.  Recombination hot spots and human disease. , 1997, Genome research.

[51]  D. Ward,et al.  Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Ikeo,et al.  Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA , 1993, Nature Genetics.

[53]  P. White,et al.  Mutation in the CYP21B gene (Ile-172----Asn) causes steroid 21-hydroxylase deficiency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Delbrück,et al.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.

[55]  J. Spivak.  Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. , 2003, Seminars in hematology.

[56]  T. Barbui,et al.  Chronic Myeloproliferative Disorders , 2003 .

[57]  K. Haigis,et al.  A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity , 2003, Nature Genetics.

[58]  S. Freier,et al.  Elevated levels of Rad51 recombination protein in tumor cells. , 2002, Cancer research.

[59]  A. Green,et al.  Myeloproliferative disorders. , 2001, Best practice & research. Clinical haematology.

[60]  J. W. Jameson,et al.  A table for the estimation of the spontaneous mutation rate of cells in culture. , 1973, Mutation research.